Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT01076634
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment
Phase 4
Completed
- Conditions
- Diabetes Type 2
- Interventions
- Drug: Insulin-LevemirDrug: Exenatide-BayettaDrug: Insulin-Levemir and Exenatide-BayettaDevice: SenseWear Pro3® armbandDevice: DexCom CGM
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 75
- Registration Number
- NCT01076842
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸MedStar Research Institute, Washington, District of Columbia, United States
Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months
Completed
- Conditions
- MenopausePostmenopausal Bleeding
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 176
- Registration Number
- NCT01076621
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 467
- Registration Number
- NCT01076647
- Locations
- 🇷🇴
Novo Nordisk Investigational Site, Satu Mare, Romania
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 456
- Registration Number
- NCT01074268
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
An Observational Study on Treatment Compliance by Children Treated With Growth Hormone
Withdrawn
- Conditions
- Growth Hormone Deficiency in ChildrenGrowth Hormone Disorder
- Interventions
- Behavioral: No treatment given
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT01068639
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 460
- Registration Number
- NCT01068678
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 460
- Registration Number
- NCT01068665
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 403
- Registration Number
- NCT01068652
- Locations
- 🇹🇳
Novo Nordisk Investigational Site, Tunisia, Tunisia
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 435
- Registration Number
- NCT01059799
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Songkla, Thailand
© Copyright 2025. All Rights Reserved by MedPath